Published in Rejuvenation Res on February 03, 2011
Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med (2011) 1.72
Therapeutic potential of human embryonic stem cell transplantation in patients with cerebral palsy. J Transl Med (2014) 1.62
Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol (2013) 1.39
Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS One (2011) 1.35
Natural history of mesenchymal stem cells, from vessel walls to culture vessels. Cell Mol Life Sci (2013) 1.31
Intranasal treatment of central nervous system dysfunction in humans. Pharm Res (2012) 1.07
Mesenchymal stem cell transplantation in multiple sclerosis. J Neurol Sci (2013) 1.04
Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ (2013) 0.99
Brain dendritic cells: biology and pathology. Acta Neuropathol (2012) 0.96
Noninvasive and targeted drug delivery to the brain using focused ultrasound. ACS Chem Neurosci (2013) 0.95
Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget (2013) 0.93
Tackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system. Stem Cell Res Ther (2013) 0.92
Molecular characterization of heterogeneous mesenchymal stem cells with single-cell transcriptomes. Biotechnol Adv (2012) 0.90
Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. Stem Cells Transl Med (2012) 0.87
Adult Mesenchymal Stem Cells: When, Where, and How. Stem Cells Int (2015) 0.87
Nanotechnology for CNS delivery of bio-therapeutic agents. Drug Deliv Transl Res (2013) 0.86
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease. Int J Nanomedicine (2012) 0.86
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination. PLoS One (2013) 0.86
Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Front Cell Neurosci (2015) 0.86
Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther (2013) 0.85
Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice. Glia (2014) 0.83
The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One (2011) 0.83
Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol (2016) 0.81
Intranasal Delivery of Neural Stem Cells: A CNS-specific, Non-invasive Cell-based Therapy for Experimental Autoimmune Encephalomyelitis. J Clin Cell Immunol (2013) 0.80
Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis. Immunology (2014) 0.80
Detection of intranasally delivered bone marrow-derived mesenchymal stromal cells in the lesioned mouse brain: a cautionary report. Stem Cells Int (2011) 0.80
The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders. Mol Psychiatry (2015) 0.79
Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson's disease: a comparison study of mononuclear and mesenchymal stem cells. Int J Med Sci (2014) 0.77
Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease. Stem Cells Transl Med (2012) 0.77
Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT. Eur Radiol (2014) 0.76
Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons. Exp Brain Res (2012) 0.76
Cell based therapy in Parkinsonism. Transl Neurodegener (2013) 0.76
Brain delivery of small interfering ribonucleic acid and drugs through intranasal administration with nano-sized polymer micelles. Med Devices (Auckl) (2015) 0.76
Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma. Stem Cell Reports (2016) 0.75
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease. Mol Neurobiol (2016) 0.75
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther (2013) 3.81
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol (2012) 3.61
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol (2007) 3.26
Using trade names: a risk factor for accidental drug overdose. Arch Intern Med (2002) 2.91
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther (2004) 2.68
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci (2010) 2.65
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Activating mutation of the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension (2004) 2.32
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics (2004) 2.32
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. Clin Pharmacol Ther (2003) 2.08
Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis (2008) 2.08
The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab (2008) 2.04
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics (2005) 1.95
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis (2010) 1.91
Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab (2014) 1.88
Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ (2002) 1.88
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics (2007) 1.84
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem (2008) 1.84
Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci (2008) 1.81
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab (2010) 1.79
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA (2005) 1.74
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med (2015) 1.68
Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem (2010) 1.66
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet (2007) 1.66
Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) (2006) 1.62
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther (2008) 1.62
Retracted Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain (2008) 1.60
Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire. J Immunol (2010) 1.59
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat (2003) 1.59
Ezetimibe and statin-associated myopathy. Ann Intern Med (2004) 1.58
Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology (2004) 1.58
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics (2008) 1.52
Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest (2007) 1.51
Proximal femur fracture in older patients--rehabilitation and clinical outcome. Age Ageing (2003) 1.51
Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis. Eur Neurol (2005) 1.50
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res (2010) 1.49
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion (2007) 1.48
Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci U S A (2005) 1.45
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci (2005) 1.43
Pharmacokinetic study of artemisinin after oral intake of a traditional preparation of Artemisia annua L. (annual wormwood). Am J Trop Med Hyg (2004) 1.43
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics (2004) 1.42
Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J Clin Nutr (2013) 1.41
Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A (2008) 1.41
Retracted Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states. Mol Pain (2012) 1.41
Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells. Proc Natl Acad Sci U S A (2013) 1.41
Vulnerability of the fetal primate brain to moderate reduction in maternal global nutrient availability. Proc Natl Acad Sci U S A (2011) 1.39
The immunosuppressive properties of mesenchymal stem cells. Transplantation (2009) 1.38
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics (2009) 1.36
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther (2004) 1.33
Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med (2013) 1.33
CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol (2004) 1.33
Pharmacogenomics of tamoxifen therapy. Clin Chem (2009) 1.31
Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet (2007) 1.31
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev (2004) 1.30
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs (2013) 1.30
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol (2002) 1.28
FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull (2007) 1.26
Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood (2012) 1.25
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther (2003) 1.23
A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci U S A (2004) 1.23
Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol (2008) 1.22
Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology (2007) 1.22
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol (2008) 1.22
Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol (2002) 1.21
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Glucocorticoid exposure at the dose used clinically alters cytoskeletal proteins and presynaptic terminals in the fetal baboon brain. J Physiol (2002) 1.19
Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res (2010) 1.19
Intranasal delivery of cells to the brain. Eur J Cell Biol (2009) 1.18